[7] In individuals with normal G6PD, standard doses typically do not cause hemolysis, but very high cumulative doses might generate oxidative stress to the point of mild hemolysis or anemia
Cardiovascular outcomes trials have demonstrated reduced rates of major adverse cardiovascular events in high-risk patients treated with liraglutide (LEADER trial) and semaglutide (SUSTAIN-6 trial)
Several widely used GLP-1 therapies, including Semaglutide and Tirzepatide, rely on pen injector systems to deliver medication accurately and safely
The overall direction of these changes moves gene expression patterns from states associated with disease and aging toward healthier profiles
A 2022 study found that participants regained twothirds of their weight loss within the first year after stopping their GLP1 usage
Years later, with additional clinical information available, Lutz came up with the suggestion that Beppu's group must have used serum/plasma from patients with one of the many autoimmune diseases that are characterized by anti-neutrophil cytoplasmic antibodies (ANCA) (Lutz, 2012)
